NCT01812954View on ClinicalTrials.gov

Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Psoriasis
Interventions
DRUG

Methotrexate

DRUG

Cyclosporins

DRUG

fumaric acid

DRUG

Acitretin

DRUG

Infliximab

DRUG

etanercept

DRUG

Adalimumab

DRUG

Ustekinumab

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Jochen Schmitt.

OTHER

NCT01812954 - Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis | Biotech Hunter | Biotech Hunter